In just under six weeks, one of the generics and biosimilars industry’s leading players will be under new management, after Teva announced that former Sandoz chief Richard Francis would take over from Kåre Schultz as president and CEO of the Israeli firm from 1 January 2023.
Teva Names Former Sandoz CEO Francis To Replace Schultz Within Weeks
Richard Francis Will Take Lead At Israeli Generics Giant From The Start Of 2023
In just under six weeks Teva will have a new president and CEO, after former Sandoz chief Richard Francis was announced as Kåre Schultz’s replacement from the start of 2023.
